glp-1 and perimenopause Weight Gain During Menopause: Solutions in the Era of GLP1-agonists GLP-1 medications peri-menopause - Star
Description
Because pancreatitis was not further specified in the cases of saxagliptin and vildagliptin, no distinction could be made between acute and chronic pancreatitis in this analysis
The first Ozempic bellwether trials are expected in 2026, and cases selected for this pool typically involve plaintiffs with strong medical documentation, clear causation, and compelling damages
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 1316 January 2025
JACC Heart Fail 4:559566
(NASDAQ: ALT) announced that pemvidutide received FDA Breakthrough Therapy designation for the treatment of MASH, further advancing development of the companys GLP-1/glucagon dual receptor agonist platform
